Stock GSK GSK PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials GSK plc Nyse

Equities

GSK

US37733W2044

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-07-16 pm EDT 		5-day change 1st Jan Change
38.9 USD +0.59% Intraday chart for GSK plc +0.78% +4.96%
Jul. 16 National Advisory Committee On Immunization Recommends RSV Vaccines, Including Arexvy, For Older Adult Populations RE
Jul. 16 GSK: RSV VACCINATION RECOMMENDED FOR CONSIDERATION BY ADULTS AGE… RE

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 88,051 66,801 80,458 58,381 59,112 61,213 - -
Enterprise Value (EV) 1 113,773 87,581 100,296 75,578 74,152 73,406 70,012 66,065
P/E ratio 19.2 x 11.8 x 18.6 x 3.93 x 11.9 x 11.3 x 9.56 x 8.61 x
Yield 4.5% 5.96% 4.98% 4.26% 4% 4.04% 4.18% 4.38%
Capitalization / Revenue 2.61 x 1.96 x 2.36 x 1.99 x 1.95 x 1.94 x 1.83 x 1.73 x
EV / Revenue 3.37 x 2.57 x 2.94 x 2.58 x 2.45 x 2.33 x 2.09 x 1.87 x
EV / EBITDA 9.51 x 9.19 x 8.85 x 7.23 x 6.37 x 6.95 x 6.01 x 5.23 x
EV / FCF 22.4 x 16.2 x 22.6 x 12.1 x 13.6 x 12.5 x 9.77 x 8.68 x
FCF Yield 4.46% 6.17% 4.42% 8.28% 7.36% 8.02% 10.2% 11.5%
Price to Book 7.35 x 4.58 x 5.34 x 5.47 x 4.4 x 3.84 x 3.16 x 2.62 x
Nbr of stocks (in thousands) 3,959,572 3,982,185 4,006,383 4,060,999 4,076,145 4,078,144 - -
Reference price 2 22.24 16.78 20.08 14.38 14.50 15.01 15.01 15.01
Announcement Date 2/5/20 2/3/21 2/9/22 2/1/23 1/31/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 33,754 34,099 34,114 29,324 30,328 31,498 33,439 35,352
EBITDA 1 11,968 9,530 11,330 10,449 11,635 10,569 11,649 12,625
EBIT 1 8,972 8,906 8,806 8,151 8,786 9,165 10,120 11,140
Operating Margin 26.58% 26.12% 25.81% 27.8% 28.97% 29.1% 30.26% 31.51%
Earnings before Tax (EBT) 1 6,221 6,968 5,442 5,628 6,064 7,329 8,693 9,644
Net income 1 4,645 5,749 4,385 14,956 4,928 5,489 6,454 7,145
Net margin 13.76% 16.86% 12.85% 51% 16.25% 17.43% 19.3% 20.21%
EPS 2 1.158 1.426 1.082 3.662 1.216 1.332 1.571 1.744
Free Cash Flow 1 5,073 5,406 4,437 6,260 5,454 5,888 7,165 7,612
FCF margin 15.03% 15.85% 13.01% 21.35% 17.98% 18.69% 21.43% 21.53%
FCF Conversion (EBITDA) 42.39% 56.73% 39.16% 59.91% 46.88% 55.71% 61.51% 60.29%
FCF Conversion (Net income) 109.21% 94.03% 101.19% 41.86% 110.67% 107.27% 111.02% 106.55%
Dividend per Share 2 1.000 1.000 1.000 0.6125 0.5800 0.6069 0.6278 0.6576
Announcement Date 2/5/20 2/3/21 2/9/22 2/1/23 1/31/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 9,527 9,780 6,929 7,829 7,376 6,951 7,178 8,147 8,052 7,363 7,505 8,455 7,992 7,530 7,810
EBITDA 1 2,406 3,317 2,639 3,561 1,602 2,732 2,622 3,351 2,930 2,992 2,510 3,117 1,784 - -
EBIT 1 1,893 2,613 2,008 2,605 1,595 2,092 2,170 2,772 1,752 2,443 2,207 2,775 1,637 2,498 2,434
Operating Margin 19.87% 26.72% 28.98% 33.27% 21.62% 30.1% 30.23% 34.02% 21.76% 33.18% 29.41% 32.82% 20.48% 33.17% 31.17%
Earnings before Tax (EBT) 1 706 2,598 896 1,012 1,626 1,907 1,987 1,791 379 1,355 1,818 2,462 1,241 - -
Net income 1 749 1,802 975 10,315 1,495 1,490 1,624 1,464 350 1,046 1,378 1,881 1,163 - -
Net margin 7.86% 18.43% 14.07% 131.75% 20.27% 21.44% 22.62% 17.97% 4.35% 14.21% 18.36% 22.24% 14.55% - -
EPS 2 0.1838 0.4488 0.2080 2.523 0.3650 0.3650 0.4010 0.3610 0.0860 0.2540 0.3330 0.4579 0.2092 - -
Dividend per Share 2 0.2875 0.1750 0.1625 0.1375 0.1375 0.1400 0.1400 0.1400 0.1600 0.1500 0.1500 0.1500 0.1500 0.1501 0.1501
Announcement Date 2/9/22 4/27/22 7/27/22 11/2/22 2/1/23 4/26/23 7/26/23 11/1/23 1/31/24 5/1/24 - - - - -
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 25,722 20,780 19,838 17,197 15,040 12,193 8,799 4,852
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.149 x 2.18 x 1.751 x 1.646 x 1.293 x 1.154 x 0.7554 x 0.3843 x
Free Cash Flow 1 5,073 5,406 4,437 6,260 5,454 5,888 7,165 7,612
ROE (net income / shareholders' equity) 75% 44.4% 38.2% 43.9% 52.5% 41.8% 38.2% 34.7%
ROA (Net income/ Total Assets) 8.9% 7.18% 5.5% 8.08% 10.5% 9.65% 10.6% 11.1%
Assets 1 52,185 80,062 79,768 185,120 46,727 56,852 60,627 64,086
Book Value Per Share 2 3.020 3.660 3.760 2.630 3.290 3.910 4.750 5.730
Cash Flow per Share 2 2.000 2.090 1.960 1.810 1.670 1.830 1.820 1.960
Capex 1 1,265 1,226 1,172 1,143 1,314 1,798 1,653 1,647
Capex / Sales 3.75% 3.6% 3.44% 3.9% 4.33% 5.71% 4.94% 4.66%
Announcement Date 2/5/20 2/3/21 2/9/22 2/1/23 1/31/24 - - -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for GSK plc

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.01 GBP
Average target price
19.88 GBP
Spread / Average Target
+32.44%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+61.53% 856B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.95% 631B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.66% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.06% 325B
ABBVIE INC. Stock AbbVie Inc.
+9.18% 297B
ROCHE HOLDING AG Stock Roche Holding AG
+5.89% 234B
NOVARTIS AG Stock Novartis AG
+16.53% 226B
AMGEN INC. Stock Amgen Inc.
+15.67% 177B
PFIZER, INC. Stock Pfizer, Inc.
+2.47% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. GSK Stock
  5. Financials GSK plc